Latest Anthrax Stories

ANNAPOLIS, Md., Dec. 6, 2011 /PRNewswire/ -- PharmAthene, Inc. (NYSE Amex: PIP) today announced that results from a Phase I clinical study of Valortim(®) were published in the December issue of Clinical and Vaccine Immunology. The American Society for Microbiology peer-reviewed journal describes clinical data supporting the potential use of Valortim(®), a fully human monoclonal antibody, as both a post-exposure prophylaxis and therapeutic treatment for...

ANNAPOLIS, Md., Nov. 28, 2011 /PRNewswire/ -- PharmAthene, Inc. (NYSE Amex: PIP), a biodefense company developing medical countermeasures against biological and chemical threats, announced today that Eric I. Richman, President and Chief Executive Officer will present at the Piper Jaffray 23rd Annual Healthcare Conference being held November 29-30, 2011. Mr. Richman will also be available to participate in one-on-one meetings at the conference. Event: Piper...

ANNAPOLIS, Md., Nov. 16, 2011 /PRNewswire/ -- PharmAthene, Inc. (NYSE Amex: PIP) announced today that data from its rPA anthrax vaccine and chemical nerve agent bioscavenger programs will be presented at the 2011 Chemical and Biological Defense Science and Technology (CBD S&T) Conference, being held in Las Vegas, NV, November 14-18, 2011. "The CBD S&T annual conference is one of the leading biodefense industry meetings and it is an honor to present among the best, new, dynamic...

A government advisory board said on Friday that for now, children will not be given an anthrax vaccine. The board said that ethical issues need to be resolved before the vaccine can be tested in children to be sure it is safe. The government has stockpiled the vaccine due to concerns of terrorist using it as a biological weapon. The National Biodefense Science Board said on Friday that a separate review board should look into the ethical issues of doing such tests in children. The...

ANNAPOLIS, Md., Oct. 31, 2011 /PRNewswire/ -- PharmAthene, Inc. (NYSE Amex: PIP) announced today further development progress of its second generation rPA anthrax vaccine, SparVax(TM). The new vaccine is being developed to provide rapid manufacturing scale-up to respond to a national security emergency. The Company completed its first cGMP manufacturing run at 1,500 liter commercial scale. Final analytical testing is ongoing and expected to be completed in December. "There is widespread...

PINE BROOK, N.J., Oct. 24, 2011 /PRNewswire/ -- Elusys Therapeutics, Inc. (Elusys), a biopharmaceutical company focused on the development of antibody therapeutics, announced today that it is initiating a new clinical study to further demonstrate the safety of Anthim (ETI-204), the company's anti-toxin in late-stage development for prevention of disease and death from exposure to inhaled anthrax. The company also announced it has successfully manufactured Anthim at commercial scale. Anthim...

WASHINGTON, Oct. 18, 2011 /PRNewswire-USNewswire/ -- Ten years ago America experienced the unthinkable when anthrax was sent through the U.S. Mail and caused the death of five individuals, including two postal employees, and caused illness in others. In the decade since this tragedy, the Postal Service decontaminated and renovated affected facilities, deployed state-of-the-art technology to detect and protect against potential threats and implemented educational programs...

ANNAPOLIS, Md., Oct. 12, 2011 /PRNewswire/ -- Today the Bipartisan WMD Terrorism Research Center (WMD Center) released its "Bio-Response Report Card" stating that the United States is not adequately prepared for the threat of a bioterrorism attack despite the attempts for improvements over the past decade. During the 10 years since the initial anthrax attacks, the government has made great progress in certain areas but has failed to meet many of the bioterrorism preparedness objectives....

OREM, Utah, Oct. 12, 2011 /PRNewswire/ -- When letters containing anthrax spores were mailed to two U.S. Senators in October 2001, the Hart Senate Office Building and two postal facilities were closed for more than a year. Remediation costs ran into the hundreds of millions of dollars. STERIPLEX Ultra kills anthrax spores in 30 minutes. Contaminated buildings may be reoccupied in hours. Unlike other sporicides, STERIPLEX Ultra is non-corrosive, non-fuming, non-toxic to inhale and not a...

The Institute of Medicine (IOM) released a report last Friday that provides guidance to U.S. public health officials to develop plans to pre-position antibiotics that can be distributed to the general public in the case of a large-scale anthrax attack. Tia Powell, M.D., director of the Montefiore Einstein Center for Bioethics and the Einstein Cardozo Masters of Science in Bioethics program, was vice-chair of the 16-member Committee Prepositioned Medical Countermeasures for the Public, which...